Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05394103 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | PHASE1 | RECRUITING | 130 | — | — | Aug 30, 2022 | Aug 30, 2026 | Aug 17, 2025 | 11 | United States, South Korea |
| Arm | Type | Description |
|---|---|---|
| Dose escalation (Q901) | EXPERIMENTAL | - |
| Q901 Single-Agent Expansion Cohorts | EXPERIMENTAL | - |
| Q901 + KEYTRUDA® (pembrolizumab) Cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Q901 | DRUG | The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter |
| KEYTRUDA® (pembrolizumab) | DRUG | KEYTRUDA® (pembrolizumab) will be administered Q6W |
Inclusion Criteria: * Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |